Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 12, 2019 4:05 PM ESTNew Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020 Received CE Mark Approval for Renevia®; Working to Identify European Commercial Partner Conducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net Proceeds Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded Additional NIH Grant for Innovative Vision Restoration Program
CARLSBAD,... More
